Cas no 79517-01-4 (Octreotide acetate)

Octreotide acetate is a synthetic octapeptide analog of somatostatin, exhibiting potent inhibitory effects on growth hormone, glucagon, and insulin secretion. Its primary therapeutic applications include the management of acromegaly and symptoms associated with neuroendocrine tumors, such as carcinoid syndrome. The acetate salt form enhances solubility and stability, facilitating subcutaneous or intravenous administration. Octreotide acetate binds with high affinity to somatostatin receptors (SSTR2 and SSTR5), prolonging its biological half-life compared to native somatostatin. Its predictable pharmacokinetics and well-characterized safety profile make it a reliable option for long-term therapy. The compound is typically supplied as a sterile lyophilized powder for reconstitution, ensuring consistent dosing and storage stability.
Octreotide acetate structure
Octreotide acetate structure
Product Name:Octreotide acetate
CAS No:79517-01-4
MF:C51H70N10O12S2
MW:1079.29130983353
MDL:MFCD08277638
CID:60093
PubChem ID:448601
Update Time:2025-06-13

Octreotide acetate Chemical and Physical Properties

Names and Identifiers

    • Octreotide
    • Octreotide Acetate
    • {d-PHE}CF{d-TRP}KTCT-OL
    • CCRIS 8708
    • d-Phe-Cys-Phe-d-Trp-Lys-Thr-Cys-Thr-OL
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide acetate (salt)
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide acetate (salt)
    • D-Phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-he
    • SMS 201995
    • sandostatin acetate
    • [R-(R*,R*)]-D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2->7)-disulfide
    • Octreotidum
    • Octreotida
    • Sandostatin
    • Longastatin
    • RWM8CCW8GP
    • Octreotidum [Latin]
    • Octreotida [Spanish]
    • Octrotide
    • Octreotide [USAN:INN:BAN]
    • Octreotide-LAR
    • Octreotide, >=98% (HPLC)
    • DEQANNDTNATYII-OULOTJBUSA-N
    • HMS2090C09
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
    • D-P
    • 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane, cyclic peptide deriv. (ZCI)
    • L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide, acetate (salt) (9CI)
    • L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide, [R-(R*,R*)]-, acetate (salt) (ZCI)
    • Mycapssa
    • Octreotide LAR
    • Sandostatin LAR
    • Sandostatin LAR Depot
    • SMS 201-995ac
    • OCTREOTIDE [INN]
    • CHEBI:7726
    • EX-A4865
    • OCTREOTIDE [USAN]
    • DB00104
    • DTXCID6028608
    • OCTREOTIDE [EP MONOGRAPH]
    • OCTREOTIDE [MI]
    • 83150-76-9
    • H01CB02
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
    • L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*,R*))-
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2->7)-disulfide
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide Cyclic (2-7)-Disulfide Acetate
    • D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl)-L-cysteinamide, Cyclic (2->7)-disulfide
    • Octreotode Acetate
    • 79517-01-4
    • MFCD00871400
    • L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-
    • Octreotidum (Latin)
    • (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
    • OCTREOTIDE [VANDF]
    • Octreotide CRS
    • 10-(4-Amino-butyl)-19-(2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carboxylic acid (2-hydroxy-1-hydroxymethyl-propyl)-amide
    • DTXSID0048682
    • AB01275486-01
    • OCTREOTIDE [WHO-DD]
    • 2-{[(13R,16S,19R)-10-(4-Amino-butyl)-19-((S)-2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carbonyl]-amino}-3-hydroxy-butyric acid
    • H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol disulfide bond acetate salt
    • CHEMBL1680
    • AKOS015994656
    • [R-(R*,R*)]-D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2-->7)-disulfide
    • 10-(4-Amino-butyl)-19-(2-amino-3-phenyl-propionylamino)-16-benzyl-7-(1-hydroxy-ethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaaza-cycloicosane-4-carboxylic acid (2-hydroxy-1-
    • Q419935
    • SMS 201,995
    • CCG-270610
    • BDBM50272772
    • SCHEMBL10044649
    • SMS995
    • Q-201501
    • SMS-995
    • SMS 201-995
    • SMS-201-995
    • AC-28733
    • 10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate
    • OCTREOTIDE (EP MONOGRAPH)
    • HS-2020
    • D-Phenylalanyl-L-cysteinyl-L-phenyl-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide Cyclic (2->7)-Disulfide
    • (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenyl-propanoyl]amino]-16-benzyl-7-[(1R)-1-hydroxyethyl]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
    • DRG-0115
    • 83150-76-9 (free base)
    • (4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
    • L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*,R*))-
    • UNII-RWM8CCW8GP
    • D-PHENYLALANYL-L-HEMICYSTYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-HEMICYSTYL-L-THREONINOL CYCLIC (2->7)-DISULFIDE
    • Octreotide acetate
    • MDL： MFCD08277638
    • Inchi： 1S/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+;/m1./s1
    • InChI Key： XQEJFZYLWPSJOV-XJQYZYIXSA-N
    • SMILES： C(=O)(O)C.C([C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@H](CO)[C@H](O)C)CSSC[C@H](NC(=O)[C@H](N)CC2C=CC=CC=2)C(=O)N[C@@H](CC2C=CC=CC=2)C(=O)N1)C1=CNC2C=CC=CC1=2

Computed Properties

  • Exact Mass: 1018.44098
  • Monoisotopic Mass: 1018.44
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 13
  • Hydrogen Bond Acceptor Count: 14
  • Heavy Atom Count: 71
  • Rotatable Bond Count: 17
  • Complexity: 1740
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 10
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 1
  • Topological Polar Surface Area: 383

Experimental Properties

  • Color/Form: No data available
  • Density: 1.395
  • Melting Point: 153-156°C
  • Boiling Point: No data available
  • Flash Point: No data available
  • Solubility: H2O: soluble
  • PSA: 332.22
  • LogP: 3.02100
  • Specific Rotation: D20 -42° (c = 0.5 in 95% acetic acid)
  • Vapor Pressure: No data available

Octreotide acetate Security Information

Octreotide acetate Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI XIAN DING Biotechnology Co., Ltd.
B-XV818-10mg
Octreotide acetate
 79517-01-4 99+%
10mg
 668CNY 2021-05-07
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
O304653-10mg
Octreotide acetate
 79517-01-4 >99%
10mg
 ￥293.90 2023-09-01
DC Chemicals
DC12298-100 mg
Octreotide acetate (SMS 201-995 (acetate))
 79517-01-4 >98%
100mg
 $200.0 2022-02-28
DC Chemicals
DC12298-250 mg
Octreotide acetate (SMS 201-995 (acetate))
 79517-01-4 >98%
250mg
 $400.0 2022-02-28
DC Chemicals
DC12298-1 g
Octreotide acetate (SMS 201-995 (acetate))
 79517-01-4 >98%
1g
 $800.0 2022-02-28
CHENG DOU FEI BO YI YAO Technology Co., Ltd.
FD030223-5g
Acetic Acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
 79517-01-4 95%
5g
 $1355 2023-09-07
TRC
O239950-5mg
Octreotide Acetate
 79517-01-4
5mg
 $75.00 2023-05-17
TRC
O239950-10mg
Octreotide Acetate
 79517-01-4
10mg
 $ 97.00 2023-09-06
TRC
O239950-25mg
Octreotide Acetate
 79517-01-4
25mg
 $224.00 2023-05-17
TRC
O239950-50mg
Octreotide Acetate
 79517-01-4
50mg
 $310.00 2023-05-17

Octreotide acetate Related Literature

Related Categories

Additional information on Octreotide acetate

Comprehensive Overview of Octreotide Acetate (CAS No. 79517-01-4): Mechanism, Applications, and Innovations

Octreotide acetate, a synthetic analog of the naturally occurring hormone somatostatin, has garnered significant attention in both clinical and research settings due to its versatile therapeutic applications. With the CAS number 79517-01-4, this compound is widely recognized for its efficacy in managing endocrine disorders, particularly acromegaly and neuroendocrine tumors (NETs). Its ability to inhibit the secretion of growth hormone (GH), glucagon, and insulin makes it a cornerstone in modern pharmacotherapy. This article delves into the molecular structure, mechanism of action, clinical uses, and emerging trends surrounding Octreotide acetate.

The molecular structure of Octreotide acetate features a cyclic octapeptide with a disulfide bridge, enhancing its stability and bioavailability compared to native somatostatin. This structural modification allows for prolonged action, reducing dosing frequency—a critical factor in patient compliance. Researchers and clinicians frequently search for "Octreotide acetate mechanism of action" or "how does Octreotide acetate work," highlighting its binding affinity to somatostatin receptors (SSTRs), particularly subtypes 2 and 5. By activating these receptors, it suppresses pathological hormone secretion and tumor proliferation, addressing conditions like carcinoid syndrome and VIPomas.

In recent years, the demand for Octreotide acetate has surged due to its expanded applications in gastroenterology and oncology. Patients and healthcare providers often inquire about "Octreotide acetate side effects" or "long-term use of Octreotide acetate," reflecting concerns about gastrointestinal disturbances, gallstone formation, and glucose metabolism alterations. However, advancements in drug delivery systems, such as long-acting release (LAR) formulations, have mitigated these challenges, offering sustained therapeutic effects with fewer adverse events.

The rise of personalized medicine and targeted therapies has further cemented Octreotide acetate's role in precision oncology. Searches for "Octreotide acetate for NETs" or "combination therapy with Octreotide acetate" underscore its integration with radiolabeled somatostatin analogs (e.g., 177Lu-DOTATATE) for advanced tumor targeting. Additionally, ongoing clinical trials explore its potential in diabetic retinopathy and polycystic liver disease, aligning with the growing interest in repurposing existing drugs for novel indications.

From a manufacturing perspective, CAS 79517-01-4 is synthesized under stringent Good Manufacturing Practice (GMP) guidelines to ensure purity and potency. Analytical techniques like high-performance liquid chromatography (HPLC) and mass spectrometry are employed to validate its chemical integrity, addressing queries such as "Octreotide acetate purity standards" or "how to identify genuine Octreotide acetate." Regulatory agencies, including the FDA and EMA, rigorously evaluate its safety profiles, reinforcing trust among stakeholders.

Looking ahead, the intersection of biotechnology and pharmacology promises to unlock new dimensions for Octreotide acetate. Innovations like nanoparticle-based delivery and gene-editing tools may enhance its therapeutic index, while real-world evidence studies address gaps in "Octreotide acetate cost-effectiveness" and "patient quality of life." As the scientific community continues to unravel its full potential, Octreotide acetate remains a paradigm of how synthetic peptides can revolutionize medicine.

79517-01-4 (Octreotide acetate) Related Products

Recommended suppliers
HANGZHOU BAIS CHEMICAL TECHNOLOGY CO., LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
HANGZHOU BAIS CHEMICAL TECHNOLOGY CO., LTD.
Zhangzhou Sinobioway Peptide Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Zhangzhou Sinobioway Peptide Co.,Ltd.
Inner Mongolia Xinhong Biological Technology Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Inner Mongolia Xinhong Biological Technology Co., Ltd
Suzhou Genelee Bio-Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Suzhou Genelee Bio-Technology Co., Ltd.
Shanghai Pearlk Chemicals Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk